Histologic evaluation of patients with dysplasia after treatment of helicobacter pylori

Histologic evaluation of patients with dysplasia after treatment of Helicobacter pylori result of screening program

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201406191155N20

Enrollment

Registered

2014-07-25

Start date

2011-03-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysplasia. Carcinoma in situ of stomach

Interventions

Intervention group take tab clarithromycin 500 miligram one number every 12 hours ,cap amoxiciline 500 miligram two numbers every 12 hours , tab bismuth sub citrate 120 miligram two numbers every 12

Treatment - Drugs

Eligibility

Sex/Gender

All

Age

50 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: All patients over 50 years in the endoscopic evaluation of gastric precancerous lesions in Lashtenesha research project; patients with displasia in pathology. Exclusion criteria: No consent to participate in the research.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Treatment of helicobacter pylori. Timepoint: Two weeks. Method of measurement: Rapid urease test.	—

Secondary

Measure	Time frame
Evaluation of dysplasia. Timepoint: Three months after helicobacter treatment. Method of measurement: Endoscopy.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarahnaz Joukar

Gastrointestinal and Liver Disease Research Center(GLDRC)

F_Jokar@gums.ac.ir+98 13 1553 5116

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026